Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Proposals are rattling around in Congress to impose a waiting period of two or three years before a new prescription drug can initiate direct-to-consumer ads. TNS Healthcare polling finds significant public support for such a measure. Forty-four percent of adults favor “a moratorium of some length”; just 9 percent oppose it, with the rest unsure either way. Respondents were also asked how much they agree (on a scale of 1 to 5) with some views about prescription-drug ads.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in